New hope for bladder cancer patients: drug combo targets tough cases
NCT ID NCT06972615
First seen Feb 18, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This study tests a combination of two chemotherapy drugs placed directly into the bladder plus an immunotherapy drug given through a vein. It is for people with high-risk non-muscle invasive bladder cancer that did not respond to or could not receive standard BCG therapy. The goal is to see if this approach can eliminate the cancer and control the disease long-term. About 37 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-MUSCLE INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BLATAM
CABA, 1123, Argentina
Conditions
Explore the condition pages connected to this study.